Division of BridgeBio Pharma Inc.
Latest From Fortify Therapeutics
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Company Type
- Parent & Subsidiaries
- BridgeBio Pharma Inc.
- Senior Management
- Contact Info
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.